How Long Does Trazodone Stay in Your System? The 3-Clock Rule

After one immediate-release dose, trazodone has a reported terminal half-life of about 5–9 hours, so five terminal half-lives equal roughly 25–45 hours; that estimate does not mark a personal “completely gone” deadline. Sleepiness may wear off sooner or persist into the next morning, while detection in blood, urine, saliva, or hair depends on the test method and cutoff, leaving no universal drug-test window.

The cleanest way to remember the answer is to picture three clocks: how long you feel the effect, how plasma concentration falls, and how long a laboratory method can detect a target. Search results often place all three on one timeline. They measure different endpoints.

That distinction matters after a bedtime dose. Waking up clear-headed answers a practical question about how you feel. It does not reveal your plasma concentration, tell a prescriber whether an interaction still matters, or predict a toxicology result.

What are the three trazodone timelines?

| Clock | What it measures | The useful answer | What it cannot prove | |---|---|---|---| | Drug effect | Sleepiness, dizziness, alertness, coordination | Sedation can begin after a dose and may carry into the next morning | Feeling awake does not prove that trazodone has been eliminated | | Pharmacokinetics | Absorption, peak plasma concentration, metabolism, half-life | Immediate-release trazodone peaks at about 1 hour fasting or 2 hours with food; its reported terminal half-life is about 5–9 hours | A study average cannot predict one person’s exact clearance time | | Analytical detection | Whether a named assay finds trazodone or a metabolite above its threshold | The answer belongs to the specimen, analyte, method, and cutoff | A label half-life cannot supply a universal urine, blood, saliva, or hair window |

Use the clock that matches your concern. If you are deciding whether you can drive, the effect clock matters. If a clinician is reviewing a dose, interaction, or adverse event, pharmacokinetics matters. If someone is ordering a test, ask which specimen, which analyte, and which cutoff.

What does trazodone’s half-life actually tell you?

A half-life is the time for a measured concentration to fall by half during a defined phase. Trazodone plasma concentrations decline in two phases. A 2015 single-dose pharmacokinetic paper by Kale and Agrawal, published in Frontiers in Pharmacology, reports an initial half-life of about 3–6 hours and a terminal half-life of about 5–9 hours, with wide variation among individuals.

The slower terminal range is the figure usually used for clearance arithmetic. After five half-lives, the mathematical remainder is 3.125% of the starting amount: half, then a quarter, then one-eighth, and so on. Using 5–9 hours yields 25–45 hours. “Completely gone” is still the wrong translation. The calculation assumes that a population estimate, one elimination phase, and your own physiology line up neatly.

The strongest argument for the five-half-life shortcut is fair: it gives a useful order of magnitude when the exact answer is unavailable. It can separate “later today” from “several days.” It fails when published as a personal expiration time, especially for a drug with biphasic decline, repeated dosing, formulation differences, and interaction-sensitive metabolism.

Around 2021, I stopped advising readers to treat five half-lives as a finish line. I had been repeating tidy arithmetic because it was easy to explain. Reading the underlying pharmacokinetic conditions changed my position; the honest output is a range tied to a study, followed by the variables that keep it from becoming your deadline.

When do immediate-release and extended-release trazodone peak?

Formulation changes the absorption clock before elimination even enters the discussion. The DailyMed prescribing information for immediate-release trazodone hydrochloride says peak plasma levels occur at about 1 hour on an empty stomach and 2 hours when taken with food. The same label says food may increase the amount absorbed, lower the maximum concentration, and lengthen the time to that maximum.

The FDA’s 2010 Oleptro extended-release label reports a very different curve. After one 300 mg extended-release tablet under fasting conditions, median time to peak concentration was 9 hours and mean apparent terminal half-life was 10 hours. A high-fat meal raised peak concentration by about 86%, although total exposure and time to peak were not significantly changed in that label study.

Those figures cannot be swapped between products. They also do not mean that a trazodone 100 mg duration is exactly twice a trazodone 50 mg duration. A larger dose can increase exposure and side effects, but dose size does not simply multiply the half-life. Check the bottle for the formulation and follow its food directions.

One more number is routinely misread. In a 1976 radiolabeled-drug study by Jauch and colleagues, 70–75% of administered radioactivity was recovered through renal excretion within 72 hours. Most urinary radioactivity represented metabolites; unchanged trazodone appeared only in minute amounts. That recovery figure describes mass balance after a labeled 25 mg dose. It is not a 72-hour urine-test window.

How long does trazodone sleepiness last?

No controlled trial turns sleepiness into a dependable hour count for one person. The DailyMed immediate-release label reports drowsiness in 23.9% of trazodone-treated inpatients versus 6.3% on placebo, and in 40.8% of outpatients versus 19.6% on placebo. These are incidence rates from controlled depression studies, not clocks.

The extended-release label adds a time frame: across an 8-week trial, somnolence or sedation was reported by 46% of participants taking Oleptro and 19% taking placebo; 4% of the Oleptro group discontinued for that reason. The doses ranged from 150 to 375 mg daily, with a mean of 310 mg during the six-week treatment period, so those percentages cannot predict a 50 mg bedtime experience.

A smaller 2011 randomized, placebo-controlled study by Roth and colleagues gets closer to the sleep question. Sixteen adults with primary insomnia took 50 mg, 30 minutes before bed, for seven days. Testing the mornings after days 1 and 7 found small but significant impairments in short-term memory, verbal learning, equilibrium, and arm muscle endurance. Next-morning function can remain affected even when subjective sleepiness feels manageable.

I learned the cost of trusting a finished surface at an overlay table: I covered a client’s lifting builder gel instead of removing it, and the concealed problem later became an infection. It was my call. In this context, the equivalent mistake is treating “I feel awake” as evidence that the underlying exposure is zero. The FDA label warns against driving or hazardous machinery until you know how trazodone affects you.

Why can the same dose produce a different timeline?

Trazodone is converted to the active metabolite m-chlorophenylpiperazine, or mCPP, through CYP3A4. A strong CYP3A4 inhibitor can raise exposure. In a DailyMed-cited study of 10 healthy participants, ritonavir 200 mg twice daily for four doses, given around a single 50 mg trazodone dose, increased trazodone peak concentration by 34%, increased total exposure 2.4-fold, lengthened half-life 2.2-fold, and cut clearance by 52%. Nausea, hypotension, and syncope occurred during coadministration.

CYP3A4 inducers can move exposure in the other direction. Alcohol and other central nervous system depressants can intensify impairment without offering a new half-life. Repeated dosing also differs from a single tablet because the DailyMed label notes that trazodone may accumulate in plasma in some patients.

Liver or kidney disease leaves extra uncertainty. Current prescribing information says trazodone has not been studied in people with hepatic impairment or renal impairment and advises caution in both groups. Age, dose, formulation, meal timing, other medicines, and the reason for treatment belong in the prescriber’s assessment; an online calculator cannot safely resolve them.

Can a test detect trazodone after you feel normal?

Yes, a sufficiently sensitive method may detect trazodone after the noticeable effect has faded. The opposite can happen near a method’s threshold. A result depends on what the laboratory targets, since unchanged drug and metabolites do not share identical concentration curves.

The Washington State Patrol Toxicology Laboratory’s May 2026 LC-MS method makes the dependency concrete. Its method accepts biological specimens including whole blood, serum, urine, and tissue homogenate. For trazodone, the stated limit of detection is 5 ng/mL, the lower limit of quantitation is 50 ng/mL, and the validated quantitative range runs from 50 to 2,000 ng/mL. Another assay can use different targets or limits.

That is why a universal claim such as “urine for X days” or “hair for 90 days” is unsound unless it names a validated assay, cutoff, analyte, specimen, dose pattern, and collection timing. Labcorp, for example, lists a dedicated urine LC-MS/MS test for trazodone and its metabolite mCPP; its public test page does not publish a time window.

I have never run a toxicology instrument, so I cannot vouch for bench workflow firsthand. I can vouch for keeping measurements attached to their methods. Cure logs, soak-off timing, and e-file bit wear become misleading when detached from the product and service conditions. In the Washington method, 5 ng/mL marks detection; reportable quantitation begins at 50 ng/mL.

When should next-day sedation be discussed with a prescriber?

Contact the prescriber when grogginess repeatedly carries into the next day, interferes with work or driving, begins after a dose or formulation change, or appears after another medicine or supplement was added. Do not drive, operate machinery, or use an e-file while your alertness or coordination is impaired. The label lists orthostatic hypotension and syncope among its warnings, so persistent dizziness or near-fainting belongs in that call.

Seek urgent help for fainting, trouble breathing, a seizure, severe confusion or agitation with fever and muscle rigidity, a fast or irregular heartbeat, or an erection lasting more than four hours. For a suspected overdose in the United States, call 911 for severe symptoms or Poison Control at 1-800-222-1222. Do not use a clearance estimate to wait out an emergency.

After regular use, changing or stopping trazodone belongs in a prescriber conversation. The label describes discontinuation symptoms including anxiety, agitation, sleep problems, dizziness, and sensory disturbances, and advises gradual dose reduction when possible. A trazodone withdrawal timeline is another individual timeline; it cannot be derived from the 5–9-hour terminal half-life alone.

Frequently asked questions

How long does it take trazodone to wear off?

The sedating effect often centers on the sleep period, yet it can carry into the next morning. Immediate-release trazodone reaches peak plasma levels at about 1 hour fasting or 2 hours with food. Avoid driving until your alertness and coordination are back to normal, regardless of elapsed hours.

What is the biggest side effect of trazodone?

Drowsiness or sedation is the most prominent common concern. DailyMed’s controlled immediate-release studies reported drowsiness in 23.9% of treated inpatients and 40.8% of treated outpatients, both above placebo. Dizziness and orthostatic hypotension also matter because sedation plus a blood-pressure drop can increase fall and driving risk.

How long will 50 mg of trazodone stay active?

A 50 mg bedtime dose may affect sleep and next-morning performance, but there is no fixed active-time window. In a seven-day controlled insomnia study, 50 mg taken 30 minutes before bed produced measurable next-morning impairments. Your response can shift with food, repeated use, age, liver function, and interacting medicines.

Does trazodone need to build up before it helps with sleep?

Sedation can occur with the first dose, so trazodone does not have to accumulate before making someone sleepy. Its antidepressant response follows a longer clinical timeline. With repeated dosing, the label says plasma accumulation can occur in some patients, which is one reason new or worsening morning grogginess deserves review.

How does an extended-release tablet change the timing?

It delays and smooths absorption. The FDA’s Oleptro label reported a median 9-hour time to peak and a mean 10-hour apparent terminal half-life after one fasting 300 mg extended-release dose. Those values cannot be applied to immediate-release 50 mg or 100 mg tablets, which peak much earlier.

Will trazodone show up on a drug test?

Only the laboratory can answer for its panel and method. A targeted LC-MS assay can detect trazodone: the Washington State Patrol method lists a 5 ng/mL detection limit and 50 ng/mL quantitation limit across several specimen types. Standard panels may target other drugs, metabolites, and thresholds, so ask for the test specification.

When should persistent next-day sedation be discussed with a prescriber?

Discuss it when sedation recurs, affects driving or work, causes falls, or starts after a dose, formulation, or medication change. Seek urgent care for fainting, breathing trouble, seizure, severe confusion with fever or rigidity, an abnormal heartbeat, or an erection lasting over four hours. Do not wait for five half-lives.